Streetbeat News

Earnings

HNST

Honest Company Inc (NASDAQ:HNST) shares surged after reporting a 10.3% increase in Q4 2023 sales to $90.26 million, surpassing analyst expectations. Growth was driven by the Digital channel, volume growth, and price gains. Diapers and Wipes revenue rose 15%, while Skin & Personal Care fell 6%, and Household & Wellness grew 28%. Digital revenue increased by 28%, but Retail revenue declined by 3%. EPS was $0.01, beating the consensus of $(0.08), and the gross margin expanded to 33.5%. The company expects FY24 revenue growth in the low-to-mid single-digit percentage and a softer first half compared to the second half of 2024.

Portfolio Pulse from Shivani Kumaresan

March 07, 2024 | 1:00 pm

SCPX

Scorpius Holdings announced a significant reduction in its Q4 2023 operating loss by over $3.3 million, or approximately 30%, compared to Q3 2023. This marks a notable improvement in the company's financial health.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 1:00 pm

HAS

LEG

T

Wall Street's most accurate analysts have provided their views on three high-dividend yielding consumer stocks: Leggett & Platt, AT&T, and Hasbro. Leggett & Platt and Hasbro reported worse-than-expected financial results, leading to price target adjustments. AT&T, however, received positive price target revisions and announced a billing credit for customers affected by a network outage.

Portfolio Pulse from Avi Kapoor

March 07, 2024 | 12:59 pm

RSI

Rush Street Interactive (NYSE:RSI) reported Q4 earnings surpassing expectations with adjusted earnings of 1 cent per share against expected losses and sales of $193.85 million beating estimates. CEO Richard Schwartz highlighted record revenues and adjusted EBITDA for 2023, with strong guidance for 2024 expecting revenues between $770 million to $830 million. Following the report, RSI shares rose 2.1%. Analysts from Needham and Wells Fargo raised their price targets on RSI to $8, maintaining positive ratings.

Portfolio Pulse from Avi Kapoor

March 07, 2024 | 12:57 pm

CIEN

Ciena reported a decline in Q1 revenue, leading to a decrease in its stock price.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 12:52 pm

LLY

NVO

Novo Nordisk's stock reached a 52-week high after revealing promising early trial data for its obesity drug amycretin, showing higher weight loss compared to its existing treatment, Wegovy. The company announced plans for a Phase 2 trial of amycretin, with results expected in early 2026. Additionally, Novo Nordisk's semaglutide demonstrated significant benefits in a kidney outcomes trial. Eli Lilly's Zepbound, a competitor drug, was also mentioned.

Portfolio Pulse from Vandana Singh

March 07, 2024 | 12:46 pm

NVO

At the Capital Markets Day event, Novo Nordisk's Chief Scientific Officer announced that the Phase 1 trial of their experimental drug Amycretin resulted in participants experiencing a weight loss of 13.1% after 12 weeks.

Portfolio Pulse from Charles Gross

March 07, 2024 | 12:45 pm

SSYS

Stratasys projects FY24 revenue between $630M-$645M, below the $644.09M estimate, and adjusted EPS of $0.12-$0.19, under the $0.26 estimate. The company anticipates improvements throughout the year, with a GAAP EPS loss of $(1.24)-$(1.01), worse than the $(0.59) estimate. This outlook assumes no further economic impediments from inflation, high interest rates, or supply chain costs.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 12:43 pm

ML

MoneyLion forecasts Q1'2024 revenues of $115M-$118M, indicating a 23-26% year-over-year growth, aligning with estimates of $115.78M. The company also anticipates its first positive GAAP EPS quarter in 2024, with an expected Adjusted EBITDA of $15M-$18M, showcasing a significant improvement in Adjusted EBITDA Margin from 7.8% in Q1 2023 to 13.0-15.3%.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 12:42 pm

WLY

John Wiley & Sons has updated its full-year 2024 financial outlook, expecting adjusted revenue to trend towards the mid-to-high end of the $1.58B-$1.63B range, against analysts' expectations of $1.691B. Additionally, the company has raised its adjusted EPS forecast from $2.05-$2.40 to $2.45-$2.65, surpassing the estimated $2.25.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 12:38 pm